Kevin Danahy, born in 1972, holds an M.S. degree from Tufts University and has over 20 years of experience in the medical technology field. He started with Pulse Biosciences as Chief Commercial Officer in February 2022, just before becoming CEO...

Kevin Danahy, born in 1972, holds an M.S. degree from Tufts University and has over 20 years of experience in the medical technology field. He started with Pulse Biosciences as Chief Commercial Officer in February 2022, just before becoming CEO in September 2022. His journey includes essential roles at notable companies like Solmetex and Zimmer Biomet, where he led exciting projects like the global launch of a robotic surgical arm. In just a year of leading Pulse Biosciences, he has shown notable ability to drive the company's goals, reflected in his bonus for completing key corporate objectives. His compensation reflects a competitive approach, with a base salary of $400,000 and bonuses tied to performance. Notably, he did not have stock awards vest in 2023, which is unusual but shows a focus on meeting performance targets rather than just financial incentives. This approach suggests he prioritizes results over quick gains. Danahy's leadership style blends industry knowledge with a hands-on attitude for improving company strategies and products. He’s all about finding better ways to enhance healthcare technology while setting solid foundations for the company’s future.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Pulse Biosciences, Inc. CEOs

P

Kevin Danahy

Ex-CEO of Pulse Biosciences, Inc.

Education

M.S. degree from Tufts University

Field of Expertise

Business & Management

Sector of Economy

Healthcare

Born

January 1, 1972 - 53 years ago

CEO of Pulse Biosciences, Inc. for

1 year 7 months (Sep 2022 - May 2024)

Previous Experience

President of Solmetex; Vice President of Global Emerging Technologies and Specialty Sales at Zimmer Biomet; Sr. Director at Intuitive Surgical; commercial leadership roles at Medtronic and Johnson & Johnson.

Rivals

Competitors/colleagues of Kevin Danahy

Holdings

See how much did Kevin Danahy make over time.

As CEO of Pulse Biosciences, Kevin Danahy has seen significant shifts in his holdings since he took office. Initially, he was granted options to acquire 450,000 shares of the company stock with an exercise price of $1.53 per share. However,...

As CEO of Pulse Biosciences, Kevin Danahy has seen significant shifts in his holdings since he took office. Initially, he was granted options to acquire 450,000 shares of the company stock with an exercise price of $1.53 per share. However, none of his stock options from prior years had vested in 2023. This suggests a challenging environment in terms of market performance and corporate goals. His personal investments show a commitment to align his interests with the company's success, but it highlights a potentially volatile situation where stock could depend heavily on future performance. A substantial portion of his wealth was tied to these holdings, but he has yet to see them benefit him due to the lack of vesting outcomes this year. As the company navigates its market strategy, Danahy’s financial future is directly related to the company's performance and strategic decisions moving ahead.

Mar 18, 2025

P

shares

PLSE @ $15.99

Insider Trading

See recent insider trades of Kevin Danahy.

PLSE

$35.11K

PLSE at $6.51/share

Nov 16, 2023

Purchase

PLSE

$14.95K

PLSE at $2.30/share

Sep 30, 2022

Purchase

Compensation History

See how much did Kevin Danahy make over time.

In 2023, Kevin Danahy's total compensation was $5,864,453, which includes a base salary of $400,000 and cash bonuses. His large bonus of $399,973 is a result of hitting essential performance goals set by the company’s board. Despite the impressive figures, he didn't have any stock awards vest this year, contrasting sharply with his previous year’s record where he received a significant bonus due to his new hire option award. The bonuses and salary structure emphasize the company’s goal-oriented compensation philosophy. Notably, despite high potential earnings, the lack of stock awards points to a structure that rewards tangible achievements over time. His compensation strategy appears built around attracting and retaining talent while ensuring that performance metrics drive payouts, putting the focus squarely on results rather than mere tenure.

Year

2023

Total Compensation

$834.73K

Salary

$433.33K

Board Justification

The compensation philosophy is designed to ensure that total compensation is reasonable and competitive, structured around the achievement of individual performance and corporate targets.

Bonus

$399.97K

Board Justification

The bonus reflects a prepayment of 2023 bonus potential by the Company’s Board of Directors, awarded in September 2023, in recognition of the Company’s exceptional progress towards successfully completing its 2023 corporate objectives.

Other

$1.42K

Board Justification

Other compensation includes various benefits and perquisites as outlined in the proxy statement.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock awards vested in 2023 as per the provided data.

Performance Metrics

The performance metrics for determining the compensation in 2023 were based on the achievement of corporate objectives.

Other Pulse Biosciences, Inc. CEOs

Here are other CEOs of Pulse Biosciences, Inc.

Darrin R. Uecker

Ex-CEO of Pulse Biosciences, Inc.

September 2015 - September 2022

Burke T. Barrett

Ex-CEO of Pulse Biosciences, Inc.

May 2024 - January 2025